Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Knox

Showing results (701-710 of 829) with videos related to

Pageof 83
Sort By:
Biomaterials|December 4, 2014
The uptake of soluble and nanoparticulate imaging isotope in model liver tumours after intra-venous and intra-arterial administrationRoss W Stephens, Karen J Knox, Lee A Philip, et al.
Current Oncology (Toronto, Ont.)|January 5, 2019
Outcomes by treatment modality in elderly patients with localized gastric and esophageal cancerA Natori, B A Chan, H W Sim, et al.
Annals of Hepatology|December 26, 2025
Effect of pembrolizumab on viral hepatitis load and transaminases in advanced hepatocellular carcinomaStephen Lam Chan, Richard S Finn, Julien Edeline, et al.
Oncotarget|April 22, 2017
Association of BRM promoter polymorphisms and esophageal adenocarcinoma outcomeGrzegorz J Korpanty, Lawson Eng, Xin Qiu, et al.
Clinical Genitourinary Cancer|February 4, 2014
A population-based overview of sequences of targeted therapy in metastatic renal cell carcinomaNimira Alimohamed, Jae-Lyn Lee, Sandy Srinivas, et al.
Journal of Viral Hepatitis|October 27, 2022
Safety, pharmacokinetics and antiviral activity of ABI-H2158, a hepatitis B virus core inhibitor: A randomized, placebo-controlled phase 1 studyKosh Agarwal, Jia Xu, Edward J Gane, et al.
The Lancet. Oncology|August 11, 2012
Conditional survival of patients with metastatic renal-cell carcinoma treated with VEGF-targeted therapy: a population-based studyLauren C Harshman, Wanling Xie, Georg A Bjarnason, et al.
Targeted Oncology|January 10, 2013
The association of clinical outcome to first-line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic renal cell carcinoma patientsMhd Y Al-Marrawi, Brian I Rini, Lauren C Harshman, et al.
Journal of Clinical Pathology|September 29, 2021
Molecular characterisation of pancreatic ductal adenocarcinoma with <i>NTRK</i> fusions and review of the literatureMichael J Allen, Amy Zhang, Prashant Bavi, et al.
Molecular Oncology|October 31, 2024
Minimally invasive determination of pancreatic ductal adenocarcinoma (PDAC) subtype by means of circulating cell-free RNAMartin Metzenmacher, Gregor Zaun, Marija Trajkovic-Arsic, et al.
Pageof 83

Showing results (701-710 of 829) with videos related to

Sort By:
Pageof 83
Biomaterials|December 4, 2014
The uptake of soluble and nanoparticulate imaging isotope in model liver tumours after intra-venous and intra-arterial administrationRoss W Stephens, Karen J Knox, Lee A Philip, et al.
Current Oncology (Toronto, Ont.)|January 5, 2019
Outcomes by treatment modality in elderly patients with localized gastric and esophageal cancerA Natori, B A Chan, H W Sim, et al.
Annals of Hepatology|December 26, 2025
Effect of pembrolizumab on viral hepatitis load and transaminases in advanced hepatocellular carcinomaStephen Lam Chan, Richard S Finn, Julien Edeline, et al.
Oncotarget|April 22, 2017
Association of BRM promoter polymorphisms and esophageal adenocarcinoma outcomeGrzegorz J Korpanty, Lawson Eng, Xin Qiu, et al.
Clinical Genitourinary Cancer|February 4, 2014
A population-based overview of sequences of targeted therapy in metastatic renal cell carcinomaNimira Alimohamed, Jae-Lyn Lee, Sandy Srinivas, et al.
Journal of Viral Hepatitis|October 27, 2022
Safety, pharmacokinetics and antiviral activity of ABI-H2158, a hepatitis B virus core inhibitor: A randomized, placebo-controlled phase 1 studyKosh Agarwal, Jia Xu, Edward J Gane, et al.
The Lancet. Oncology|August 11, 2012
Conditional survival of patients with metastatic renal-cell carcinoma treated with VEGF-targeted therapy: a population-based studyLauren C Harshman, Wanling Xie, Georg A Bjarnason, et al.
Targeted Oncology|January 10, 2013
The association of clinical outcome to first-line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic renal cell carcinoma patientsMhd Y Al-Marrawi, Brian I Rini, Lauren C Harshman, et al.
Journal of Clinical Pathology|September 29, 2021
Molecular characterisation of pancreatic ductal adenocarcinoma with <i>NTRK</i> fusions and review of the literatureMichael J Allen, Amy Zhang, Prashant Bavi, et al.
Molecular Oncology|October 31, 2024
Minimally invasive determination of pancreatic ductal adenocarcinoma (PDAC) subtype by means of circulating cell-free RNAMartin Metzenmacher, Gregor Zaun, Marija Trajkovic-Arsic, et al.
Pageof 83